RGLS has 36-month beta value of 1.17. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for RGLS is 52.59M, and currently, short sellers hold a 4.26% ratio of that float. The average trading volume of RGLS on March 12, 2025 was 458.39K shares.
RGLS) stock’s latest price update
The stock of Regulus Therapeutics Inc (NASDAQ: RGLS) has decreased by 0.00 when compared to last closing price of 1.33.Despite this, the company has seen a loss of -1.48% in its stock price over the last five trading days. prnewswire.com reported 2025-03-04 that SAN DIEGO, March 4, 2025 /PRNewswire/ — Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today announced that members of the management team will participate in a fireside chat at the Leerink Partners 2025 Global Healthcare Conference on Tuesday, March 11 th at 3:40 p.m. ET. The live event and replay of the presentation will be available under “Events and Presentations” through the investor relations section of the Company’s website at https://ir.regulusrx.com/events and archived for 90 days following the presentation date.
RGLS’s Market Performance
Regulus Therapeutics Inc (RGLS) has seen a -1.48% fall in stock performance for the week, with a 10.83% gain in the past month and a -16.87% plunge in the past quarter. The volatility ratio for the week is 6.38%, and the volatility levels for the past 30 days are at 7.91% for RGLS. The simple moving average for the past 20 days is 2.86% for RGLS’s stock, with a -16.98% simple moving average for the past 200 days.
Analysts’ Opinion of RGLS
Many brokerage firms have already submitted their reports for RGLS stocks, with Oppenheimer repeating the rating for RGLS by listing it as a “Outperform.” The predicted price for RGLS in the upcoming period, according to Oppenheimer is $7 based on the research report published on August 02, 2024 of the previous year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see RGLS reach a price target of $6. The rating they have provided for RGLS stocks is “Outperform” according to the report published on March 18th, 2024.
B. Riley FBR Inc. gave a rating of “Neutral” to RGLS, setting the target price at $1 in the report published on March 28th of the previous year.
RGLS Trading at 2.49% from the 50-Day Moving Average
After a stumble in the market that brought RGLS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.91% of loss for the given period.
Volatility was left at 7.91%, however, over the last 30 days, the volatility rate increased by 6.38%, as shares surge +17.70% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -16.87% lower at present.
During the last 5 trading sessions, RGLS fell by -1.48%, which changed the moving average for the period of 200-days by -30.73% in comparison to the 20-day moving average, which settled at $1.2930. In addition, Regulus Therapeutics Inc saw -15.82% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RGLS starting from Hagan Joseph P, who purchase 50,000 shares at the price of $1.09 back on Jan 30 ’25. After this action, Hagan Joseph P now owns 260,808 shares of Regulus Therapeutics Inc, valued at $54,260 using the latest closing price.
BALTIMORE DAVID, the Director of Regulus Therapeutics Inc, purchase 19,610 shares at $1.06 during a trade that took place back on Jan 30 ’25, which means that BALTIMORE DAVID is holding 22,169 shares at $20,787 based on the most recent closing price.
Stock Fundamentals for RGLS
Current profitability levels for the company are sitting at:
- -147.67 for the present operating margin
- 0.19 for the gross margin
The net margin for Regulus Therapeutics Inc stands at -137.84. The total capital return value is set at -0.51. Equity return is now at value -72.36, with -63.31 for asset returns.
Based on Regulus Therapeutics Inc (RGLS), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -75.53. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -172.85.
Currently, EBITDA for the company is -30.88 million with net debt to EBITDA at 0.63. When we switch over and look at the enterprise to sales, we see a ratio of 204.86. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.65.
Conclusion
To put it simply, Regulus Therapeutics Inc (RGLS) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
